Company / Working Capital
Axsome Therapeutics, Inc. Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$210.2M
FY2025
5-year range
$63.5M / $365.4M
FY2021-FY2025
Trend
-17.6%
vs FY2024
Sector context
#167 of 213
Health Care
What the data says
Axsome Therapeutics, Inc.'s working capital of $210M is lower than 78% of companies in the Health Care sector (FY2025). Working Capital has fluctuated over the past 10 years, ranging from $4M in FY2018 to $365M in FY2023.
Based on SEC 10-K filings.
$210M in FY2025 with a 5-year CAGR of +5.5%.
Declined from $365M to $210M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +12.1%
- 5-Year CAGR
- +5.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 22% in Health CareTop 78% of 213This company $210.2M Sector average $934.6M
▼
-77.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +5.5%, indicating consistent growth.
- In FY2025, working capital decreased 17.6% year-over-year.
- Ranks #167 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $210.2M | -17.6% |
| FY2024 | $255.0M | -30.2% |
| FY2023 | $365.4M | +145.1% |
| FY2022 | $149.1M | +134.9% |
| FY2021 | $63.5M | -60.5% |
| FY2020 | $160.6M | -18.0% |
| FY2019 | $195.9M | +4358.8% |
| FY2018 | $4.4M | -81.0% |
| FY2017 | $23.1M | -25.0% |
| FY2016 | $30.8M | -33.6% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026